Healthcare Stocks Gain Momentum as Drug Innovation and Defensive Demand Drive Sector Rotation

Healthcare Outperformance Highlights a Shift in Market Leadership

Healthcare is attracting renewed investor attention as pharmaceutical innovation, improving business fundamentals, and a rotation away from higher-volatility technology stocks reshape market sentiment.

The sector outperformed the broader market during the week ended October 23, 2026, with biotechnology stocks posting particularly strong gains. While established pharmaceutical companies continue to benefit from recurring demand for medicines, investors are also weighing clinical breakthroughs, patent expirations, and the ability of drugmakers to sustain future growth.

Key Points

• Healthcare outperforms the broader market: Pharmaceutical and biotechnology stocks benefit from renewed investor interest, supported by defensive demand and company-specific developments.
• Drug innovation drives growth expectations: Eli Lilly's obesity treatments, Merck's personalized cancer vaccine, and AbbVie's expanding immunology franchise highlight important changes across the industry.
• Earnings and clinical results take center stage: A busy reporting calendar, upcoming FDA decisions, and concerns about patent expirations will test investor confidence in pharmaceutical growth prospects.

Healthcare Outperforms as Investors Look Beyond Technology

Healthcare stocks delivered a strong performance during the week ended October 23, even as the broader stock market declined.

The Health Care Select Sector SPDR Fund (XLV) gained approximately 1.5%, while biotechnology ETFs posted even stronger advances. In contrast, the S&P 500 and Nasdaq-100 declined.

The divergence suggests that investors are becoming more selective about where they place capital.

After an extended period of attention on artificial intelligence and technology infrastructure, pharmaceutical companies are gaining visibility for their established businesses and expanding treatment portfolios.

Healthcare also offers a different set of growth drivers. Demand for medicines is less directly tied to the economic cycle than spending in many other industries, while successful clinical trials can create opportunities for individual companies.

Eli Lilly Benefits From Strong Obesity Drug Demand

Eli Lilly (LLY) has been among the most prominent healthcare performers, reaching new all-time highs as investors respond to its expanding diabetes and obesity business.

The company's Mounjaro and Zepbound treatments continue to drive substantial revenue growth, helping Lilly raise its full-year financial outlook.

Demand for these medicines has also supported profitability, allowing the company to benefit from rising sales while improving operating efficiency.

Lilly is expanding beyond its established injectable treatments.

Its newer oral obesity medicine, Foundayo, is gaining attention, while investigational treatments such as retatrutide could broaden the company's portfolio.

The company also continues developing medicines outside the obesity market, including treatments in oncology and immunology.

Lilly's next earnings report, scheduled for October 29, will provide an important update on demand, pricing, and the performance of its newer products.

Clinical Innovation Supports the Broader Healthcare Rally

The renewed interest in healthcare extends beyond weight-loss medications.

Biotechnology companies are advancing treatments for cancer, autoimmune diseases, and other serious medical conditions.

Goldman Sachs healthcare analyst Asad Haider recently highlighted the importance of clinical progress and pharmaceutical dealmaking in supporting the sector.

Drugmakers are increasingly seeking innovative treatments through internal research, partnerships, and acquisitions.

These developments have helped pharmaceutical and biotechnology stocks outperform the broader market this year, although individual companies continue to experience significant differences in performance.

Why Are Merck, AbbVie, and Amgen Drawing Investor Attention?

For established pharmaceutical companies, one of the biggest challenges is maintaining growth as older blockbuster medicines lose patent protection.

When a patent expires, competing treatments can enter the market, often reducing sales of the original medicine.

This makes the development of new drugs essential to long-term financial performance.

Merck, AbbVie, and Amgen are approaching this challenge in different ways.

Merck Advances a New Generation of Cancer Treatments

Merck (MRK) is attracting attention for its oncology research, particularly its collaboration with Moderna (MRNA) on a personalized cancer vaccine.

The experimental treatment, called intismeran autogene, is designed around genetic characteristics found in an individual patient's tumor.

It is being tested alongside Merck's established cancer medicine Keytruda.

Recent Phase 3 results showed that the combination reduced the risk of melanoma returning or causing death compared with Keytruda alone.

The findings represent an important development for personalized cancer treatment, although regulatory approval is still required.

Merck is working toward a potential filing before the end of 2026, with possible approval in 2027.

The timing matters because Keytruda faces a major patent expiration in 2028.

Merck is developing additional cancer treatments and pursuing partnerships to help offset the potential loss of revenue as competing medicines enter the market.

AbbVie Finds Growth Beyond Humira

AbbVie (ABBV) is already navigating a major patent transition.

Its former blockbuster treatment Humira has faced increasing competition from biosimilars, resulting in declining sales.

However, AbbVie's newer immunology medicines, Skyrizi and Rinvoq, are expanding rapidly.

Together, the two treatments generated more than $8 billion in second-quarter revenue, helping offset Humira's decline.

Their growth demonstrates how newer medicines can replace revenue from older products when pharmaceutical companies successfully develop and commercialize additional treatments.

AbbVie has also continued increasing its dividend, supported by its expanding pharmaceutical business.

Nevertheless, the company is becoming more dependent on Skyrizi and Rinvoq, making their continued performance particularly important.

Amgen Expands Its Pipeline While Managing Older Products

Amgen (AMGN) faces similar pressures as several established medicines encounter biosimilar competition.

Sales of its older treatments Prolia and XGEVA have declined, but newer products are helping support the business.

Repatha, a cholesterol-lowering treatment, continues growing, while Amgen is also expanding its portfolio of biosimilar medicines.

The company is pursuing opportunities in obesity treatment through MariTide, an investigational drug currently undergoing advanced clinical testing.

Amgen continues generating substantial cash flow and has maintained a long record of dividend increases.

However, its significant debt remains an important financial consideration as it invests in research, new treatments, and business development.

What Comes Next for Healthcare Stocks?

The coming week will bring an unusually active schedule of pharmaceutical earnings and clinical announcements.

These developments will provide a clearer picture of whether recent healthcare strength is supported by continued business growth.

Major Pharmaceutical Earnings Take Center Stage

Eli Lilly, Merck, Bristol Myers Squibb (BMY), and Gilead Sciences (GILD) are scheduled to report earnings on October 29.

AbbVie, AstraZeneca (AZN), Regeneron Pharmaceuticals (REGN), and Sanofi (SNY) follow on October 30.

For Lilly, attention will focus on obesity treatment demand and whether the company raises its financial outlook.

Merck's report will provide insight into Keytruda sales and the contribution of newer medicines.

AbbVie's results will show whether Skyrizi and Rinvoq continue offsetting declining Humira revenue.

Gilead's report will offer an update on its HIV treatment business, which remains an important source of revenue and cash flow.

Across the industry, investors will be looking beyond headline earnings figures to understand which companies are successfully expanding their product portfolios.

Clinical Trials Could Influence Individual Stocks

Several biotechnology companies also face important clinical developments.

Oruka Therapeutics (ORKA) is expected to release psoriasis treatment results, while Incyte (INCY) will discuss findings from its cancer research programs.

Beam Therapeutics (BEAM) is scheduled to provide an update on an experimental gene-editing treatment.

Regulatory decisions are also approaching for Inovio Pharmaceuticals (INO) and Agios Pharmaceuticals (AGIO).

Unlike established pharmaceutical companies with multiple marketed products, smaller biotechnology businesses can be particularly sensitive to clinical results.

A successful trial can improve expectations for future commercial opportunities, while disappointing findings can significantly change a company's outlook.

Patent Expirations Keep Pharmaceutical Dealmaking in Focus

Beyond the immediate earnings calendar, patent expirations remain a central issue for the pharmaceutical industry.

Major medicines such as Merck's Keytruda and Bristol Myers Squibb's Opdivo face the loss of exclusivity before the end of the decade.

To prepare, companies are investing in research and exploring acquisitions, licensing agreements, and partnerships.

These transactions allow established drugmakers to access treatments developed by smaller biotechnology companies.

However, higher interest rates and regulatory uncertainty can influence the cost and timing of major deals.

The ability to replace aging blockbuster medicines with successful new treatments will remain an important measure of pharmaceutical performance.

What It Means for Investors

Healthcare's recent outperformance reflects a combination of defensive demand and company-specific growth opportunities.

Established pharmaceutical companies often generate recurring revenue from medicines used to treat chronic and serious illnesses. This can make their businesses less sensitive to some economic fluctuations.

However, the sector faces risks that differ from those affecting technology or industrial companies.

Patent expirations can reduce revenue from successful medicines, while clinical trial setbacks can delay or prevent the launch of new treatments.

The distinction is particularly important when comparing large pharmaceutical companies with smaller biotechnology businesses.

Merck's outlook depends partly on its ability to expand beyond Keytruda. AbbVie is demonstrating progress in replacing Humira revenue, while Amgen is balancing newer treatments against declining sales from older products.

Eli Lilly, meanwhile, continues benefiting from strong obesity treatment demand, although its recent stock performance reflects elevated expectations for future growth.

Dividend-paying pharmaceutical companies also attract attention from income-oriented investors, but dividend sustainability ultimately depends on cash generation, financial obligations, and the performance of their drug portfolios.

The upcoming earnings reports and clinical announcements will provide additional insight into how these businesses are progressing.

Conclusion

Healthcare stocks are gaining renewed attention as investors shift toward established pharmaceutical businesses and companies developing innovative treatments.

Eli Lilly's obesity franchise remains a major source of industry growth, while Merck's personalized cancer vaccine research highlights advances in oncology.

AbbVie and Amgen demonstrate how pharmaceutical companies are adapting to patent expirations by expanding their treatment portfolios.

The coming week will bring important earnings reports, clinical results, and regulatory developments that could influence individual stocks and broader sector sentiment.

Healthcare's recent outperformance signals growing investor interest beyond technology, but sustained performance will depend on the industry's ability to turn medical innovation into durable revenue and profitability.

FAQs

Why are healthcare stocks outperforming the broader market?

Healthcare stocks have benefited from renewed interest in defensive sectors, strong pharmaceutical demand, and advances in drug development. During the week ended October 23, healthcare and biotechnology ETFs gained while major market benchmarks declined.

What is driving Eli Lilly's growth?

Eli Lilly's growth is being driven primarily by strong demand for its diabetes and obesity treatments, including Mounjaro and Zepbound. The company is also developing additional oral and injectable medicines to expand its portfolio.

Why is Merck's cancer vaccine important?

Merck and Moderna are developing a personalized cancer vaccine designed to help prevent melanoma from returning. Positive Phase 3 results support further development, potentially adding an important treatment to Merck's oncology portfolio as Keytruda approaches patent expiration.

How are AbbVie and Amgen responding to patent expirations?

AbbVie is replacing declining Humira sales with growing revenue from Skyrizi and Rinvoq. Amgen is expanding newer medicines and its biosimilar portfolio while managing competition affecting older treatments.

What should investors watch in healthcare next week?

Major pharmaceutical earnings, clinical trial updates, and FDA decisions will be important developments. Investors will focus on treatment demand, new drug pipelines, profitability, and the ability of companies to sustain growth.

This article was created with AI assistance and reviewed by an editor. For details, please refer to our Terms of Use.

Go Beyond the Market Brief with Market Edge

Follow SharperTrades’ complete approach to trading and investing, combining active trade opportunities through Block Orders, long-term research through Stock Investor, and structured market education through the Swing Trading Masterclass. Try Market Edge for $19 your first month →

Explore Research with Stock Investor

Stock Investor is SharperTrades’ platform for long-term investing research and portfolio management. Members receive research reports, portfolio updates, conviction tracking, and in-depth analysis designed to support disciplined investment decisions.

Explore Active Trading & Income Strategies

Block Orders tracks institutional activity and highlights active trade setups and price behavior across long and short opportunities.

For options-focused traders, Essential Option Income provides a structured approach to options income strategies, while Pro Option Trader offers a broader range of options strategies and trade opportunities.

Think More Clearly with SteadyCapital

SteadyCapital is SharperTrades’ decision-support system for long-term investors, built around the SteadyCapital Method™. Review investment ideas, challenge assumptions, evaluate valuation and risk, compare companies, and think through important buy, hold, add, trim, or sell decisions before you act.

Risk Disclosure

All content is provided for educational purposes only and does not constitute investment advice. Trading involves risk, and past performance is not indicative of future results. Please review our full Risk Disclosure for additional information.